Common misconceptions about Good Supply Practice (GSP) in clinical settings

Good Supply Practice (GSP) often gets overshadowed by the rigorous attention given to Good Clinical Practice (GCP) and Good Laboratory Practice (GLP), yet it forms the invisible backbone of any successful clinical study. Many organizations mistakenly believe that once a product is manufactured under GMP, it can be shipped to the site with minimal oversight. This article aims to clarify five critical misconceptions that can jeopardize data integrity and patient safety if left unaddressed.

The Myth of "It Works at the Factory, So It Works on Site"

One of the most pervasive fallacies in the industry is the assumption that manufacturing quality guarantees supply chain quality. While Good Manufacturing Practice (GMP) ensures the product is made correctly, it does not guarantee that the product will remain unchanged during transport, storage, or handling at the clinical site. A sterile injectable might pass all release tests in the lab, only to degrade due to temperature fluctuations in a poorly monitored clinic warehouse.

The Critical Role of Storage Conditions

Proper storage is not merely a logistical checkbox; it is a fundamental component of GSP that directly impacts data validity. If the temperature records at a clinical site do not match the product specification, the data generated using that product becomes suspect. Regulatory bodies like the FDA and EMA increasingly scrutinize temperature excursions, and sponsors must have robust systems in place to detect and correct these issues immediately.

The Peril of Outsourcing Without Oversight

Many sites outsource their supply chain functions to third-party vendors to reduce costs or increase efficiency. However, there is a dangerous misconception that signing a contract automatically delegates all GSP responsibilities. The sponsor retains ultimate responsibility for the quality of the clinical supply. If the vendor fails to train the site staff on proper handling procedures or fails to provide adequate documentation upon delivery, the site bears the brunt of the regulatory scrutiny. The onus is on the sponsor to verify that the vendor's GSP systems are robust enough to protect the study's integrity.

Ignoring the Human Element in Cold Chain Management

GSP is often viewed as a purely technical or logistical challenge, ignoring the human factor. In clinical settings, especially in lower-resource regions or busy hospital wards, the reliability of the supply chain can hinge on the training and motivation of local staff. A well-designed cooler may fail if the person managing it is unaware of the specific temperature requirements for the investigational medicinal product (IMP). Misconceptions here often lead to "just-in-time" delivery strategies that result in last-minute rushes, increasing the risk of handling errors and cold chain breakages.

The False Security of Bulk Supply Agreements

Some organizations rely on bulk supply agreements with commercial manufacturers to avoid managing their own supply chains during clinical trials. The prevailing belief is that if a company sells millions of units, their quality control is sufficient. This overlooks the specific needs of a clinical trial, which may require customized labeling, specific packaging materials, or unique stability data for the exact trial duration. Commercial products are often stored for years, whereas clinical supplies might need to be used immediately after arrival, making long-term stability data irrelevant for short-term clinical use.

The Undervaluing of Return and Disposal Protocols

Finally, there is a tendency to underestimate the importance of managing returned or expired supplies. In clinical trials, unused IMPs must be disposed of in a manner that complies with both environmental regulations and GSP requirements. Failure to document the destruction of these materials or to track returns properly creates significant gaps in the audit trail. These gaps can lead to accusations of data fabrication or mishandling of sensitive materials, potentially halting the trial or inviting regulatory warnings.

In summary, Good Supply Practice is an active, continuous process rather than a static checklist. To ensure patient safety and data integrity, sponsors must move beyond these misconceptions and implement a proactive, comprehensive supply management strategy that considers the entire lifecycle of the clinical material.

  • Verify vendor qualification regularly: Do not rely on initial audits; schedule periodic on-site inspections.
  • Train site staff specifically on GSP: Generic training is insufficient; staff must understand the specific requirements of the trial product.
  • Implement real-time monitoring: Relying on periodic logs is dangerous; continuous data logging is essential for cold chain integrity.
  • Document every step: From receipt to disposal, every action regarding the IMP must be clearly recorded.
  • Conduct periodic risk assessments: Re-evaluate supply chain risks every quarter as protocols change or new products are introduced.

By addressing these common misunderstandings, pharmaceutical companies can build a resilient supply chain that supports the highest standards of clinical research.

Related reading